Meeting Patients with Hepatitis C Where They Are: Lessons from the HIV Epidemic in the USA
- 1Division of General Internal Medicine, Department of Medicine, University of California, Los Angeles, CA USA
- 2Division of Infectious Diseases, Department of Medicine, University of California, Los Angeles, CA USA
Abstract
Despite the advent of well-tolerated and curative direct-acting antivirals (DAAs) for hepatitis C virus (HCV), rates of acute HCV infections have increased in the past decade, persistently falling short of national eradication goals. HCV elimination strategies have adopted the care cascade, a framework originating in HIV care, to assess where patients are lost at each step of diagnosis, linkage to care, receipt of DAAs, and achievement of sustained virologic response. Interventions aimed at strengthening the HIV care cascade, including community-based testing, rapid initiation of treatment, and federal funding for treatment and housing, have been instrumental in increasing the number of people living with HIV who achieve viral suppression. Widescale uptake of HCV treatment, meanwhile, continues to face barriers, from payor restrictions to provider hesitance to treat patients who use drugs, despite evidence demonstrating high rates of treatment completion among this population. HIV care has critically reframed treatment nonadherence as a need for more support, rather than as a value judgment and as a reflection of the patient’s ability to receive treatment. We advocate for this approach to be applied to HCV care to provide broader and more equitable access to HCV treatment, and ultimately cure, particularly for marginalized populations such as people who use drugs (PWUD). We propose solutions for increasing HCV treatment uptake using lessons from HIV care, including using a test and treat approach to initiate DAAs during hospital admission.
Related
- Why Outcomes Diverge in Chronic Hepatitis B with Steatotic Liver Disease: Lessons from Within-Study Contrasts
- Cuban epidemic neuropathy: lessons learned from scientific and political controversies
- Age as a significant prognostic factor in patients meeting the global ARDS definition but not the Berlin definition
- Closing the hepatitis equity gap for migrants: implementation lessons from three European countries
- Hepatitis A outbreak response in a vulnerable setting: lessons from southern Portugal
BibTeX
@article{scialli2026meeting,
title = {{Meeting Patients with Hepatitis C Where They Are: Lessons from the HIV Epidemic in the USA}},
author = {Anna C. Scialli and Tara Vijayan},
journal = {Journal of General Internal Medicine},
year = {2026},
month = aug,
doi = {10.1007/s11606-026-10629-7},
url = {https://doi.org/10.1007/s11606-026-10629-7},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Meeting Patients with Hepatitis C Where They Are: Lessons from the HIV Epidemic in the USA
AU - Anna C. Scialli
AU - Tara Vijayan
PY - 2026
DA - 2026/08/17
JO - Journal of General Internal Medicine
DO - 10.1007/s11606-026-10629-7
UR - https://doi.org/10.1007/s11606-026-10629-7
AB - Despite the advent of well-tolerated and curative direct-acting antivirals (DAAs) for hepatitis C virus (HCV), rates of acute HCV infections have increased in the past decade, persistently falling short of national eradication goals. HCV elimination strategies have adopted the care cascade, a framework originating in HIV care, to assess where patients are lost at each step of diagnosis, linkage to care, receipt of DAAs, and achievement of sustained virologic response. Interventions aimed at strengthening the HIV care cascade, including community-based testing, rapid initiation of treatment, and federal funding for treatment and housing, have been instrumental in increasing the number of people living with HIV who achieve viral suppression. Widescale uptake of HCV treatment, meanwhile, continues to face barriers, from payor restrictions to provider hesitance to treat patients who use drugs, despite evidence demonstrating high rates of treatment completion among this population. HIV care has critically reframed treatment nonadherence as a need for more support, rather than as a value judgment and as a reflection of the patient’s ability to receive treatment. We advocate for this approach to be applied to HCV care to provide broader and more equitable access to HCV treatment, and ultimately cure, particularly for marginalized populations such as people who use drugs (PWUD). We propose solutions for increasing HCV treatment uptake using lessons from HIV care, including using a test and treat approach to initiate DAAs during hospital admission.
SN - 0884-8734
SN - 1525-1497
ER -